SHSE:603669 (China)
Â
Class A
Â¥
6.01
+0.11 (+1.86%)
Sep 22
Business Description
Lionco Pharmaceutical Group Co Ltd
SIC : 2834
ISIN : CNE1000022R8
Share Class Description:
SHSE:603669: Class ATotal Employee Number:
284Compare
Compare
Traded in other countries / regions
603669.China Index Membership
SSE Composite Index IPO Date
2015-05-28Description
Lionco Pharmaceutical Group Co Ltd is a Chinese pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products, with a focus on injectable drugs and clinical nutrition therapies. Its product portfolio includes amino acid and carbohydrate infusion products such as alanyl glutamine for injection, fructose for injection, inverted sugar for injection, xylitol for injection, riboflavin sodium phosphate for injection, and water-soluble vitamin for injection. These products are primarily used in hospital settings for parenteral nutrition and supportive care, serving patients who require intravenous feeding or vitamin supplementation. The company's customers are mainly hospitals, medical institutions, and pharmaceutical distributors across China. Lionco generates revenue through the manufacture and sale of these injectable pharmaceutical products, supported by ongoing research and development of additional clinical nutrition and injection-based therapies.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.51 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.5 | |||||
Debt-to-EBITDA | -2.81 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.07 | |||||
Beneish M-Score | -2.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.2 | |||||
3-Year EBITDA Growth Rate | -0.9 | |||||
3-Year EPS without NRI Growth Rate | 2.6 | |||||
3-Year FCF Growth Rate | -7.8 | |||||
3-Year Book Growth Rate | -18.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.15 | |||||
9-Day RSI | 65.61 | |||||
14-Day RSI | 59.11 | |||||
3-1 Month Momentum % | 12.99 | |||||
6-1 Month Momentum % | 26.27 | |||||
12-1 Month Momentum % | -5.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.22 | |||||
Quick Ratio | 1.05 | |||||
Cash Ratio | 0.36 | |||||
Days Inventory | 130.64 | |||||
Days Sales Outstanding | 248.09 | |||||
Days Payable | 245.84 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 53.06 | |||||
Operating Margin % | -7.87 | |||||
Net Margin % | -33.4 | |||||
EBITDA Margin % | -27.97 | |||||
FCF Margin % | -27.43 | |||||
OCF Margin % | -26.48 | |||||
ROE % | -20.33 | |||||
ROA % | -11.83 | |||||
ROIC % | -3.76 | |||||
3-Year ROIIC % | -132.02 | |||||
ROC (Joel Greenblatt) % | -18.85 | |||||
ROCE % | -14.39 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 150.25 | |||||
PS Ratio | 10.46 | |||||
PB Ratio | 6.68 | |||||
Price-to-Tangible-Book | 7.81 | |||||
EV-to-EBIT | -38.84 | |||||
EV-to-EBITDA | -56.54 | |||||
EV-to-Revenue | 10.87 | |||||
EV-to-FCF | -39.62 | |||||
Price-to-GF-Value | 0.83 | |||||
Price-to-Projected-FCF | 60.1 | |||||
Price-to-Median-PS-Value | 1.19 | |||||
| Price-to-Net-Current-Asset-Value | 60.1 | |||||
Earnings Yield (Greenblatt) % | -2.57 | |||||
FCF Yield % | -2.62 | |||||
Forward Rate of Return (Yacktman) % | -15.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lionco Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 408.334 | ||
| EPS (TTM) (Â¥) | -0.194 | ||
| Beta | 0.4291 | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.24 | ||
| Volatility % | 45.27 | ||
| 14-Day RSI | 59.11 | ||
| 14-Day ATR (Â¥) | 0.320723 | ||
| 20-Day SMA (Â¥) | 5.421 | ||
| 12-1 Month Momentum % | -5.52 | ||
| 52-Week Range (Â¥) | 4.01 - 8.4 | ||
| Shares Outstanding (Mil) | 712.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lionco Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lionco Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| 1.4:1 Stock Split | 2020-05-26 | 7.56 (+0.76%) | ||
| 1.4:1 Stock Split | 2019-06-06 | 5.80 (+0.09%) | ||
| 1.4:1 Stock Split | 2018-05-10 | 7.65 (-5.79%) |
Show
Entries
Lionco Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Lionco Pharmaceutical Group Co Ltd(SHSE:603669)'s stock price today?
The current price of SHSE:603669 is ¥6.01. The 52 week high of SHSE:603669 is ¥8.40 and 52 week low is ¥4.01.
When is next earnings date of Lionco Pharmaceutical Group Co Ltd(SHSE:603669)?
The next earnings date of Lionco Pharmaceutical Group Co Ltd(SHSE:603669) is .
Does Lionco Pharmaceutical Group Co Ltd(SHSE:603669) pay dividends? If so, how much?
Lionco Pharmaceutical Group Co Ltd(SHSE:603669) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers